Literature DB >> 14524486

Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960-2000.

S M Chow1, S C K Law, S K Au, O Mang, S Yau, K T Yuen, W H Lau.   

Abstract

The clinical features, management and outcome of 1348 patients diagnosed with differentiated thyroid carcinoma in Queen Elizabeth Hospital, Hong Kong, were analysed according to the period of diagnosis: A (before 1980), B (1981-1990) and C (1991-2000). As time advanced, ratio of papillary carcinoma (PTC) to follicular carcinoma (FTC) increased (A:B:C = 1.6: 3.1: 7.2). The mean size of the primary tumour decreased (A:B:C = 3.5 cm: 2.8 cm: 2.5 cm), with a greater percentage of microcarcinoma of 1 cm or less (A:B:C = 5.1%: 16.1%: 21.7%). At presentation, the incidence of lymph-node metastasis decreased (A:B:C = 32.7%: 31.6%: 24.8%) and that of distant metastasis decreased (A:B:C = 9%: 6.1%: 5.3%). Bilateral surgical resection was more commonly used (A:B:C = 62.8%: 89.1%: 94.8%) than lobectomy (A:B:C = 26.3%: 2.8%: 1.8%). Radiation treatment, radioactive iodine (131I; RAI) and external radiotherapy (EXT), was more commonly used (A:B:C = 53.2%: 74.7%: 85.1%). RAI was used in 84.3% (A:B:C = 50%: 71.2%: 84.3%) and EXT in 14.5% of patients in the past decade (A:B:C = 10.9%: 8.7%: 14.5%). The proportion of patients who adopted a bilateral surgery and RAI treatment increased gradually with time (A:B:C = 33%: 68%: 83.8%). The 5-year cause-specific survival (A:B:C = 90.2%: 93.7%: 95.7%), locoregional failure-free survival (A:B:C = 72.6%: 82.9%: 91.6%) and distant metastasis failure-free survival (A:B:C = 84.5%: 89.1%: 92.6%) were improved. However, the period of diagnosis was not found to be an important explanatory variable (i.e. P > 0.05) in Cox regression after adjusting for other factors, indicating that the improvement was probably related to the temporal trend of other factors: presentation at earlier stage, increased ratio of PTC:FTC and more aggressive management by bilateral surgery and radiation therapy.

Entities:  

Mesh:

Year:  2003        PMID: 14524486     DOI: 10.1016/s0936-6555(03)00066-9

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  17 in total

1.  Retrospective Analysis of 255 Papillary Thyroid Carcinomas ≤2 cm: Clinicohistological Features and Prognostic Factors.

Authors:  Pedro Marques; Valeriano Leite; Maria João Bugalho
Journal:  Eur Thyroid J       Date:  2014-12-06

2.  Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size.

Authors:  Kwan Ju Lee; Yun Jung Cho; Say Jun Kim; Sang Chul Lee; Jeong Goo Kim; Chang Joon Ahn; Dong Ho Lee
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

3.  Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series.

Authors:  Patrícia Sabino de Matos; Ana Paula C Ferreira; Laura S Ward
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

4.  Clinical aggressiveness of incidental and non-incidental thyroid cancer.

Authors:  A Ciampolillo; M Bellacicco; A Natalicchio; A Pezzolla; P Trerotoli; L Grammatica; G Achille; F Giorgino
Journal:  J Endocrinol Invest       Date:  2010-09-02       Impact factor: 4.256

5.  RET polymorphisms might be the risk factors for thyroid cancer.

Authors:  Rui-Xue Huang; Fei Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  Mortality-related factors in 1056 radioiodine-treated patients with well-differentiated thyroid cancer in southern Thailand.

Authors:  Tada Yipintsoi; Teerapon Premprabha; Alan Geater; Tanyaluck Thientunyakij; Suchitra Thongmak
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

7.  Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades.

Authors:  Bo Youn Cho; Hoon Sung Choi; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; Kyung Won Kim; Ka Hee Yi; June-Key Chung; Yeo-Kyu Youn; Nam Han Cho; Do Joon Park; Chang-Soon Koh
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

8.  Risk-stratified management of well-differentiated thyroid cancers: a review of experience from a single institution, 1990-2003.

Authors:  M H Chew; G Chan; M M A Siddiqui; B C Tai; R Sivanandan; K C Soo; D T H Lim
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

9.  Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?

Authors:  Carmelo Nucera; Alfredo Pontecorvi
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-27       Impact factor: 5.555

10.  Cervical masses as manifestation of papillary thyroid carcinomas </=10 mm in diameter, in patients with unknown thyroid disease.

Authors:  Kalliopi Pazaitou-Panayiotou; Maria Alevizaki; Maria Boudina; Apostolos Drimonitis; Anastasia Kiziridou; Iraklis Vainas
Journal:  Thyroid Res       Date:  2008-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.